Wire · opportunities
FDA Expands Anktiva Approval in Bladder Cancer
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 14 October 2026 · Fusion42 review
The FDA has expanded approval of Anktiva combined with BCG to treat adults with BCG-unresponsive non-muscle invasive bladder cancer, now including those with high-grade papillary-only tumors. This decision is based on extrapolated efficacy data from patients with carcinoma in situ, marking a new regulatory approach.
This Wire brief sits within Fusion42's coverage of Medtech, and 10 sources have reported it between 14 Oct 2026 and 17 Oct 2026.
◆ ◆ The Wire takeaway
You can now target a broader bladder cancer population with Anktiva plus BCG, opening the market beyond carcinoma in situ cases. This shift invites you to rethink your clinical trials or product positioning for BCG-unresponsive papillary tumours.
◆ Coverage
10 sources · first reported 14 Oct 2026 · latest 17 Oct 2026
◆ Related on Wire
◆ Topics